ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Samsung Biologics to make coronavirus antibody drug for US startup

Treatment set for clinical trials and mass production next year

Once the treatment is approved by health authorities, Samsung Biologics will shift to mass production next year. (Photo courtesy of the company)

SEOUL -- Samsung Biologics has reached an agreement to produce a potential coronavirus treatment on behalf of an American biotechnology startup, with output scaled up in 2021 pending clearance from health authorities.

Under the $362 million deal with Vir Biotechnology announced Friday, Samsung Biologics will manufacture antibody treatments that have received preliminary approval from the U.S. Food and Drug Administration. Clinical trials are set to begin within the year.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more